Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14

Hsieh James J.; Marker Mahtab; Chen David

首页> 外文期刊>European urology >Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14

【24h】

Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14

机译：回复叶磊，塞尔迪尔·伊尔兹和明峰陈的信中的信Re：James J. Hsieh，David Chen，Patricia Wang，等。随机试验的基因组生物标志物比较第一线Everolimus和Sunitinib在转移性肾细胞癌患者中的基因组生物标志物。 EUR UROL 2017; 71：405-14

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European urology》 |2017年第3期|共2页
作者
Hsieh James J.; Marker Mahtab; Chen David;
展开▼
作者单位

Washington Univ Mol Oncol St Louis MO USA;

Novartis Oncol E Hanover NJ USA;

Novartis Oncol E Hanover NJ USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献

1. Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14 [J] . Hsieh James J., Marker Mahtab, Chen David European urology . 2017,第3期

机译：回复叶磊，塞尔迪尔·伊尔兹和明峰陈的信中的信Re：James J. Hsieh，David Chen，Patricia Wang，等。随机试验的基因组生物标志物比较第一线Everolimus和Sunitinib在转移性肾细胞癌患者中的基因组生物标志物。 EUR UROL 2017; 71：405-14
2. Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Mejean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842-3 Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell Carcinoma [J] . Santoni Matteo, Montironi Rodolfo, Battelli Nicola, European urology . 2019,第3期

机译：回复Michael Staehler，Dena Battle，Axel Bex，Hans Hammers和Daniel George的信Re：Arnaud Mejean，Alain Ravaud，Simon Thezenas，等。单独的Sunitinib或在转移性肾细胞癌中肾切除术后。 EUR UROL 2018; 74：842-3淋巴细胞表型和自由基肾切除术治疗肾细胞癌治疗的患者的激进肾切除术
3. Reply to the Reply to Andrew J. Portis and Matthew F. Bultitude's Letter to the Editor re: Zhangqun Ye, Guohua Zeng, Huan Yang, et al. Efficacy and Safety of Tamsulosin in Medical Expulsive Therapy for Distal Ureteral Stones with Renal Colic: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Eur Urol 2018; 73: 385-91 [J] . Portis Andrew J., Bultitude Matthew F. European urology . 2018,第2期

机译：回复对Andrew J. Portis和Matthew F. Bultition的信的回复给编辑Re：Zhangqun Ye，Guohua Zeng，Huan Yang等。 Tamsulosin在肾上腺肠道远端输尿管中医学驱逐治疗的功效和安全性：多中心，随机，双盲，安慰剂对照试验。 EUR UROL 2018; 73：385-91
4. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma [O] . James J. Hsieh, David Chen, Patricia I. Wang, -1

机译：一线依维莫司和舒尼替尼治疗转移性肾细胞癌患者的随机试验的基因组生物标志物
5. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma [O] . James J. Hsieh, David Chen, Patricia I. Wang, 2017

机译：随机试验的基因组生物标志物比较第一线艾莫姆斯和孙尼替尼在转移性肾细胞癌患者中的肝癌

Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14

著录项

相似文献

相关主题

期刊订阅